Aptose Biosciences Inc. enters into at-the-market sales agreement with Cantor Fitzgerald & Co.
March 28, 2018
30.00 Million USD
On March 28, 2018, Aptose Biosciences Inc. announced that it has entered into an at-the-market ("ATM") sales agreement with Cantor Fitzgerald & Co. pursuant to which Aptose will have the option to issue and sell through Cantor, from time to time, common shares of Aptose through ATM distributions on the NASDAQ Capital Market. In conjunction with the ATM, Aptose has filed a prospectus supplement to its short form base shelf prospectus dated March 7, 2018 with the Ontario Securities Commission and with the U.S. Securities and Exchange Commission qualifying the offer and sale of common shares having an aggregate offering price of up to US$30 million.
Aptose is a biopharmaceutical company focused on the discovery, research and development of anti-cancer therapies.
McCarthy Tétrault LLP advised Aptose with a team led by Charles-Antoine Soulière that included Myreille Gilbert and Xin Gao (Business), and Marie-Soleil Landry (Tax).